Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.49 which represents a decrease of $-1.53 or -1.63% from the prior close of $94.02. The stock opened at $93.81 and touched a low ...

Catch up on all the biggest pharma news to hit the industry last month, with stories spanning the US election, new ...

GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.

Timely remdesivir treatment in immunocompromised patients infected with COVID-19 is associated with improved survival outcomes.

Novartis, Gilead, Roche and Takeda commit to new partners in a spate of mid-sized collaborations this week. Meanwhile, ...

University of Colorado professor Leslie Leinwand thinks studying python hearts could lead to treatments for human heart disease ...

The stock's fall snapped an eight-day winning streak.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...

The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

Remdesivir treatment reduces the risk for 30-day COVID-19-related hospital readmission among all patients discharged alive from initial hospitalization.

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...